NCT00642759View on ClinicalTrials.gov

Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

carboplatin

Given by infusion on day 1 of each 3 week cycle for a maximum of 6 cycles

DRUG

Nab-paclitaxel

Given by infusion once weekly (days 1, 8 and 15) of each three week cycle for a maximum of 6 cycles

DRUG

Bevacizumab

IV infusion

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Celgene Corporation

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT00642759 - Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter